VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01

Trial Profile

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs VXM-01 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors VAXIMM
  • Most Recent Events

    • 07 Jun 2016 Results from extension part of this trial (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 19 May 2016 According to an VAXIMM media release, data from this trial will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 05 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top